BGHL (GBP): NAV(s)

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
104
BGHL (GBP): NAV(s)

                                      BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares

The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.

 

Close of business 12 Jun 2018.

 

Estimated NAV

 

  Euro Shares Sterling Shares
Estimated NAV €  23.7451 £  21.0499
Estimated MTD return  0.40 %  0.42 %
Estimated YTD return  1.28 %  1.65 %
Estimated ITD return  137.45 %  110.50 %

 

NAV and returns are calculated net of management and performance fees

 

Market information

 

Euro Shares Amsterdam (AEX) London (LSE)
Market Close €  19.80 N/A
Premium/discount to estimated NAV  -16.61 % N/A
     
Sterling Shares Amsterdam (AEX) London (LSE)
Market Close N/A GBX 1,735.00
Premium/discount to estimated NAV N/A  -17.58 %

 

 

Transactions in own securities purchased into treasury

 

Ordinary Shares Euro Shares Sterling Shares
Number of shares N/A N/A
Average Price N/A N/A
Range of Price N/A N/A

           

                                           

Liquidity Enhancement Agreement Euro Shares Sterling Shares
Number of shares N/A N/A
Average Price N/A N/A

 

BGHL Capital

 

BGHL Ordinary Shares Euro Shares Sterling Shares
Shares Outstanding  28,758,219  632,590
Held in treasury N/A N/A
Shares Issued  28,758,219  632,590

 

Estimated BG Fund NAV

Class B Euro Shares (estimated) €  190.9555

The Class B Euro Shares of BG Fund are not subject to investment manager fees, as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL.

 

For further information please contact:

Boussard & Gavaudan Investment Management, LLP. Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.com

 

The Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the "Shares") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.

This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute, or form part of, any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.

Neither the Company nor BG Fund ICAV has been, and neither will be, registered under the US Investment Company Act of 1940, as amended (the "Investment Company Act"). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"). Consequently any such securities may not be offered, sold or otherwise transferred within the United States or to, or for the account or benefit of, US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.

You should always bear in mind that:

all investment is subject to risk;

results in the past are no guarantee of future results;

the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; and

if you are in any doubt about the contents of this communication or if you consider making an investment decision, you are advised to seek expert financial advice.

 

This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.

 

 

 

Attachment

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Caldolor®: A Breakthrough in Opioid-Sparing Pain Relief for Seniors

Updated Category News Views 183

Revolutionizing Pain Management for Older Adults This comprehensive analysis reveals groundbreaking findings about Caldolor® (intravenous ibuprofen) and its effectiveness in managing pain for older adults. As the population ages, the need for safer alternatives for pain relief has significantly increased. Recent studies showcase a marked reduction in opioid consumption...

Continue Reading
Certara Stock Faces Challenges as it Hits a 52-Week Low

Updated Category News Views 120

Certara's Stock Market Performance Certara Inc. (NASDAQ: CERT), recognized as a frontrunner in biosimulation technology, has recently seen its stock price fall to a concerning 52-week low of $10.35. This price decline highlights a notable shift from its previous valuation, indicating a tumultuous time for shareholders. Over the last year, Certara's stock has experienced a...

Continue Reading
Urgent Reminder for WM Technology Shareholders on Lead Plaintiff Deadline

Updated Category News Views 159

Important Information for WM Technology Shareholders The Gross Law Firm is reaching out to shareholders of WM Technology, Inc. (NASDAQ: MAPS). This notice serves as a crucial reminder regarding the upcoming deadline for appointing a lead plaintiff in the class action lawsuit involving the company. Who Should Contact the Gross Law Firm? If you have purchased shares of MAPS...

Continue Reading
Nebraska Medicine Enhances Cancer Services with Expansion

Updated Category News Views 82

Nebraska Medicine Strengthens Cancer Care Network Nebraska Medicine is making significant strides in enhancing cancer care with the introduction of its new facility, Nebraska Medicine Fred & Pamela Buffett Cancer Center – Kearney. This expansion aims to serve communities across various regions, and it heralds an exciting phase for cancer treatment and research in the...

Continue Reading
Sunshine Silver's IPO: A Spotlight on Silver's Future

Updated Category News Views 8

Sunshine Silver Steps into the Spotlight Ah, the thrill of a fresh IPO. Sunshine Silver Mining & Refining Company, rolling under the ticker SSMR, has announced its initial public offering price—$13.50 a share, with 20 million shares up for grabs. This development has sure piqued the interest of traders eyeing some silver lining. The Figures That Matter Alright, let’s...

Continue Reading